BURZYNSKI RESEARCH COM USD0.001 (BZYR)

0.07
OTC Markets
Prev Close 0.07
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.06 / 0.16
Exchange OTC Markets
Shares Outstanding 131.45B
Market Cap 9.20M
Div & Yield N.A. (N.A)

Burzynski Research Institute, Inc. Announces The Launch Of A New Clinical Trial In Diffuse Intrinsic Brainstem Glioma

Burzynski Research Institute, Inc. (BRI) announced today that it has begun patient enrollment into an FDA-reviewed and IRB-approved, open-label, single-arm phase 2 study of Antineoplastons A10 and AS2-1 in patients > 3...

Burzynski Research Institute, Inc. Announces Favorable Objective Response Rates And Overall Survival In Adults With Anaplastic Astrocytoma Following Antineoplastons A-10 And AS2-1

Burzynski Research Institute, Inc. (BRI) announced today the publication of "A Phase II Study of Antineoplastons A10 and AS2-1 (ANP) in Adult Patients with Primary Brain Tumors - Final Report (Protocol BT-09)".

Burzynski Research Institute, Inc. Announces Publication Of Phase II Results In Adults With Recurrent Anaplastic Astrocytoma

Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain tumors and other cancers, announces the publication of data by...

Burzynski Research Institute, Inc. Announces Publication Of Phase II Results In Patients With Non-Diffuse Intrinsic Pontine Glioma

Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain and brainstem tumors and other cancers, announces the publication...

Burzynski Research Institute, Inc. Announces Publication Of Phase II Results In Adults With Newly-Diagnosed Anaplastic Astrocytoma

Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with rare brain tumors and other cancers, announces the publication of data...

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials Of ANP For Inoperable Brain Tumors At The Congress

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2 nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China.